Compare
AbbVie vs Vericel (ABBV vs VCEL)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Vericel (VCEL) +46.8%; so far this year the figures are +27.5% and +51.7%.
AbbVie is the larger company by market value, about 184.6 times the size of Vericel.
On trailing earnings, ABBV trades at 50.1 times and VCEL at 85.3 times.
Revenue grew +10.7% at ABBV and +25.3% at VCEL over the last year.
ABBV yields 2.38%. VCEL pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | VCEL | |
|---|---|---|
| Price | $291.31 | $54.62 |
| 1-day | +1.07% | +5.48% |
| YTD | +27.49% | +51.68% |
| 1 year | +34.39% | +46.83% |
| 3 years | +104.47% | +56.06% |
| Market cap | $514.9B | $2.8B |
| P/E | 50.1 | 85.3 |
| P/S | 7.80 | 8.60 |
| P/B | — | 7.26 |
| Revenue growth | +10.70% | +25.30% |
| EPS growth | +340.20% | +156.00% |
| Gross margin % | 73.7 | 74.5 |
| Net margin % | 15.7 | 10.3 |
| ROE % | — | 8.7 |
| Debt / equity | — | 0.03 |
| FCF yield % | 3.7 | 2.1 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.43 |
| RSI (14) | 59.7 | 78.4 |
| Technical rating |